gliclazide has been researched along with Electrolytes in 1 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Electrolytes: Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Bommel, EJM | 1 |
| Geurts, F | 1 |
| Muskiet, MHA | 1 |
| Post, A | 1 |
| Bakker, SJL | 1 |
| Danser, AHJ | 1 |
| Touw, DJ | 1 |
| van Berkel, M | 1 |
| Kramer, MHH | 1 |
| Nieuwdorp, M | 1 |
| Ferrannini, E | 1 |
| Joles, JA | 1 |
| Hoorn, EJ | 1 |
| van Raalte, DH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus[NCT02682563] | Phase 4 | 44 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measured in kilograms (NCT02682563)
Timeframe: 12 weeks
| Intervention | kilograms (Mean) |
|---|---|
| Dapagliflozin 10mg Once Daily | 93.7 |
| Gliclazide Modified Release 30mg Once Daily | 99.6 |
Calculated from urinary and plasma para-aminohippurate concentrations, ERPF in ml/min (NCT02682563)
Timeframe: 12 weeks
| Intervention | ml/min (Mean) |
|---|---|
| Dapagliflozin 10mg Once Daily | 639 |
| Gliclazide Modified Release 30mg Once Daily | 678 |
Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of glucose. Fractional excretion in % of filtered glucose (NCT02682563)
Timeframe: 12 weeks
| Intervention | % of filtered glucose (Mean) |
|---|---|
| Dapagliflozin 10mg Once Daily | 31.1 |
| Gliclazide Modified Release 30mg Once Daily | 0.6 |
Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of potassium. Fractional excretion in % of filtered potassium (NCT02682563)
Timeframe: 12 weeks
| Intervention | % of filtered potassium (Mean) |
|---|---|
| Dapagliflozin 10mg Once Daily | 13.6 |
| Gliclazide Modified Release 30mg Once Daily | 11.8 |
Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of sodium. Fractional excretion in % of filtered sodium (NCT02682563)
Timeframe: 12 weeks
| Intervention | % of filtered sodium (Mean) |
|---|---|
| Dapagliflozin 10mg Once Daily | 0.74 |
| Gliclazide Modified Release 30mg Once Daily | 0.66 |
Calculated from urinary and plasma inulin concentrations, GFR in ml/min (NCT02682563)
Timeframe: 12 weeks
| Intervention | ml/min (Mean) |
|---|---|
| Dapagliflozin 10mg Once Daily | 104 |
| Gliclazide Modified Release 30mg Once Daily | 109 |
KIM-1 (ng/mmol) measured in urine as a marker of renal damage (NCT02682563)
Timeframe: 12 weeks
| Intervention | ng/mmol (Median) |
|---|---|
| Dapagliflozin 10mg Once Daily | 0.25 |
| Gliclazide Modified Release 30mg Once Daily | 0.265 |
NGAL (ng/mmoll) measured in urine as a marker of renal damage (NCT02682563)
Timeframe: 12 weeks
| Intervention | ng/mmol (Median) |
|---|---|
| Dapagliflozin 10mg Once Daily | 3.76 |
| Gliclazide Modified Release 30mg Once Daily | 3.79 |
Blood pressure will be measured using an automated oscillometric blood pressure device (Dinamap®) in mmHg (NCT02682563)
Timeframe: 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Dapagliflozin 10mg Once Daily | 129.2 |
| Gliclazide Modified Release 30mg Once Daily | 131.1 |
Calculated from measured urinary albumin and creatinin concentrations, in mg/mmol (NCT02682563)
Timeframe: 12 weeks
| Intervention | mg/mmol (Median) |
|---|---|
| Dapagliflozin 10mg Once Daily | 0.88 |
| Gliclazide Modified Release 30mg Once Daily | 0.54 |
1 trial available for gliclazide and Electrolytes
| Article | Year |
|---|---|
SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
Topics: Acid-Base Equilibrium; Ammonium Compounds; Benzhydryl Compounds; Bicarbonates; Blood Glucose; Citrat | 2020 |